Search

… will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic …

… Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology. This month several ProQRians …

… on developing potential medicines using our Axiomer ® RNA editing platform technology. Strategic collaborations …

… the industry. Leiden student learning about our Axiomer™ RNA editing technology. The visit began with general …

… on developing potential medicines using our Axiomer RNA editing platform technology. Strategic collaborations …

… medicines” The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the … Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology …

… review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also … Agency (EMA) and US Food & Drug Administration (FDA). RNA editing technology – accelerate development of the …

… Always excited about RNA therapies He is one of the founders of ProQR, but even … to choose RNA therapy over gene therapy or even gene editing using CRISPR-Cas, the latest hype. And the main … are still expanding our toolbox. We can now do single base RNA editing, turning a single A nucleotide into an I. It …